



iCo Therapeutics Inc
TSX-V: 'ICO'

760-777 Hornby St. Tel: 604-602-9414
Vancouver, BC Fax: 604-602-9699
V6Z 1S4 Canada www.icotherapeutics.com

iCo Therapeutics is a 'search and development' company with a mission to license drugs and redefine them for new or expanded indications.

CORPORATE SNAPSHOT

28.2 M Shares Outstanding
Invested Capital to Date: ~\$13 M
Largest Shareholder: ISIS Pharmaceuticals~14%
Management ~16%

Canadian Comparables:
Protox Therapeutics (PRX)
Allon Therapeutics (NPC)

INVESTMENT HIGHLIGHTS

Demonstrated acquisition strategy:
3 clinical drug candidates in 2 years

Reprofiling model (Aspreva, Celgene)

↓ Risk ↓ Cost ↓ Time

Billion dollar markets addressing life and sight – threatening diseases, including:

Diabetes-related blindness
Allergies
Fungal & Parasitic Infections

Experienced Management & Board

2009 Outlook

iCo- 007

- Early trial results presented at conferences
- Final patient enrolled

iCo- 009

- Continued animal studies
- Safety & Toxicology studies, Manufacturing
- Prepare for Phase I clinical trial

2008 Milestones

iCo- 007

- ✓ Addition of clinical advisors
- ✓ Complete 1st cohort dosing
- ✓ Presentation at influential int'l conferences
- ✓ Interim safety data released

iCo- 008

- ✓ Assembly of Ph II Advisory Committee
- ✓ Drug product ready for 'fill/finish' manufacturing

iCo- 009

- ✓ Receipt of supporting grants
- ✓ FDA meeting re: Phase I study plan
- ✓ Exercise option to license
- ✓ Pre-Phase I meeting with FDA

CLINICAL STAGE ASSETS

Worldwide exclusive rights

iCo- 007 Diabetes-related blindness (Phase I)
(ISIS Pharmaceuticals)

iCo- 008 Severe Ocular Allergy (Phase II)
(Astra Zeneca/CAT)

iCo- 009 Systemic Fungal Infections & VL
(Preclinical) (UBC)